| The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: From antioxidant to epigenetic therapy C Grinán-Ferré, A Bellver-Sanchis, V Izquierdo, R Corpas, J Roig-Soriano, ... Ageing Research Reviews 67, 101271, 2021 | 196 | 2021 |
| Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer’s disease mouse model C Griñán-Ferré, L Marsal-García, A Bellver-Sanchis, SM Kondengaden, ... Aging (Albany NY) 11 (23), 11591, 2019 | 67 | 2019 |
| A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice J Companys-Alemany, AL Turcu, A Bellver-Sanchis, MI Loza, JM Brea, ... Pharmaceutics 12 (3), 284, 2020 | 61 | 2020 |
| Cognitive decline and BPSD are concomitant with autophagic and synaptic deficits associated with G9a alterations in aged SAMP8 mice F Vasilopoulou, A Bellver-Sanchis, J Companys-Alemany, J Jarne-Ferrer, ... Cells 11 (16), 2603, 2022 | 17 | 2022 |
| Synergistic Neuroprotective Effects of a Natural Product Mixture against AD Hallmarks and Cognitive Decline in Caenorhabditis elegans and an SAMP8 Mice Model C Griñán-Ferré, A Bellver-Sanchis, M Olivares-Martín, ... Nutrients 13 (7), 2411, 2021 | 16 | 2021 |
| The contribution of epigenetic inheritance processes on age-related cognitive decline and Alzheimer’s disease A Bellver-Sanchis, M Pallàs, C Griñán-Ferré Epigenomes 5 (2), 15, 2021 | 16 | 2021 |
| Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease J Pereira-Sousa, B Ferreira-Lomba, A Bellver-Sanchis, ... Neurobiology of Disease 152, 105278, 2021 | 13 | 2021 |
| Advancing personalized medicine in neurodegenerative diseases: The role of epigenetics and pharmacoepigenomics in pharmacotherapy C Griñán-Ferré, A Bellver-Sanchis, A Guerrero, M Pallàs Pharmacological Research 205, 107247, 2024 | 8 | 2024 |
| Structure‐Based Virtual Screening and in vitro and in vivo Analyses Revealed Potent Methyltransferase G9a Inhibitors as Prospective Anti‐Alzheimer's Agents A Bellver‐Sanchis, B Singh Choudhary, J Companys‐Alemany, Sukanya, ... ChemMedChem 17 (13), e202200002, 2022 | 8 | 2022 |
| G9a inhibition promotes neuroprotection through GMFB regulation in Alzheimer’s disease A Bellver-Sanchis, Q Geng, G Navarro, PA Ávila-López, ... Aging and disease 15 (1), 311, 2024 | 7 | 2024 |
| A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer’s Disease Mice Models J Jarne-Ferrer, C Griñán-Ferré, A Bellver-Sanchis, S Vázquez, ... Pharmaceuticals 15 (8), 908, 2022 | 6 | 2022 |
| Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics C Griñán‐Ferré, J Jarné‐Ferrer, A Bellver‐Sanchís, S Codony, ... CNS Neuroscience & Therapeutics 30 (4), e14511, 2024 | 3 | 2024 |
| Neuroprotective effects of G9a inhibition through modulation of peroxisome-proliferator activator receptor gamma-dependent pathways by miR-128 A Bellver-Sanchis, PA Ávila-López, I Tic, D Valle-García, M Ribalta-Vilella, ... Neural Regeneration Research 19 (11), 2532-2542, 2024 | 2 | 2024 |
| Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer’s Agent A Jana, A Bellver-Sanchis, C Griñán-Ferré, DR Banerjee ACS Medicinal Chemistry Letters 14 (11), 1531-1536, 2023 | 2 | 2023 |
| Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer’s agent S Sukanya, A Bellver-Sanchis, BS Choudhary, S Kumar, B Pérez, ... Bioorganic Chemistry 153, 107811, 2024 | 1 | 2024 |
| Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity … M Toledano-Pinedo, A Porro-Pérez, L Schäker-Hübner, F Romero, ... Journal of Medicinal Chemistry 67 (18), 16533-16555, 2024 | 1 | 2024 |
| Deletion of Gadd45a Expression in Mice Leads to Cognitive and Synaptic Impairment Associated with Alzheimer’s Disease Hallmarks C Griñán-Ferré, J Jarne-Ferrer, A Bellver-Sanchis, M Ribalta-Vilella, ... International Journal of Molecular Sciences 25 (5), 2595, 2024 | 1 | 2024 |
| RNA-seq and miRNA-seq data from pharmacological inhibition of the G9a/GLP histone methyltransferase complex with UNC0642 in SAMP8 mice S Pawar, A Bellver-Sanchis, C Griñán-Ferré Data in Brief 36, 107114, 2021 | 1 | 2021 |
| G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials A Bellver‐Sanchis, M Ribalta‐Vilella, A Irisarri, P Gehlot, BS Choudhary, ... Medicinal Research Reviews, 2025 | | 2025 |
| Caenorhabditis elegans Models of Neurodegenerative Diseases A Bellver-Sanchis, A Irisarri, C Griñán-Ferré Methods in Neurodegenerative Disease Drug Discovery, 259-282, 2024 | | 2024 |
